Rosemont Pharmaceuticals acquires Lucis Pharma
With the acquisition, Rosemont will expand its existing portfolio and gain access to the new pipeline of products, providing lifesaving pharmaceuticals across the UK and within overseas markets.
Eli Lilly and Company has entered a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide (a LAPS GLP-2 analogue), worldwide excluding Korea.